- Home
- WINA vs DAWN Comparison
WINA vs DAWN Comparison
Compare WINA & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINA
- DAWN
- Stock Information
- Founded
- WINA 1988
- DAWN 2018
- Country
- WINA United States
- DAWN United States
- Employees
- WINA N/A
- DAWN N/A
- Industry
- WINA Other Specialty Stores
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- WINA Consumer Discretionary
- DAWN Health Care
- Exchange
- WINA Nasdaq
- DAWN Nasdaq
- Market Cap
- WINA 1.4B
- DAWN 1.6B
- IPO Year
- WINA 1993
- DAWN 2021
- Fundamental
- Price
- WINA $399.62
- DAWN $13.34
- Analyst Decision
- WINA Strong Buy
- DAWN Strong Buy
- Analyst Count
- WINA 1
- DAWN 7
- Target Price
- WINA $445.00
- DAWN $36.17
- AVG Volume (30 Days)
- WINA 18.0K
- DAWN 1.3M
- Earning Date
- WINA 10-16-2024
- DAWN 10-30-2024
- Dividend Yield
- WINA 0.65%
- DAWN N/A
- EPS Growth
- WINA N/A
- DAWN N/A
- EPS
- WINA 10.93
- DAWN N/A
- Revenue
- WINA $81,781,000.00
- DAWN $101,953,000.00
- Revenue This Year
- WINA $0.47
- DAWN N/A
- Revenue Next Year
- WINA $4.86
- DAWN $44.21
- P/E Ratio
- WINA $36.17
- DAWN N/A
- Revenue Growth
- WINA N/A
- DAWN N/A
- 52 Week Low
- WINA $330.25
- DAWN $11.30
- 52 Week High
- WINA $451.30
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- WINA 54.75
- DAWN 38.64
- Support Level
- WINA $386.88
- DAWN $12.86
- Resistance Level
- WINA $403.14
- DAWN $13.71
- Average True Range (ATR)
- WINA 11.50
- DAWN 0.77
- MACD
- WINA -1.16
- DAWN -0.25
- Stochastic Oscillator
- WINA 38.90
- DAWN 12.24
About WINA Winmark Corporation
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.